Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) CEO Brian Lian sold 115,859 shares of the stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $57.58, for a total transaction of $6,671,161.22. Following the completion of the transaction, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at approximately $135,596,696.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Viking Therapeutics Price Performance
Viking Therapeutics stock opened at $53.05 on Friday. The stock’s 50 day moving average is $54.99 and its 200 day moving average is $57.43. Viking Therapeutics, Inc. has a one year low of $8.28 and a one year high of $99.41. The firm has a market cap of $5.85 billion, a P/E ratio of -57.04 and a beta of 1.03.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. During the same quarter last year, the company posted ($0.19) earnings per share. Equities analysts anticipate that Viking Therapeutics, Inc. will post -0.99 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Research Report on VKTX
Institutional Trading of Viking Therapeutics
A number of large investors have recently bought and sold shares of the business. Lindbrook Capital LLC boosted its position in shares of Viking Therapeutics by 370.7% during the 1st quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 278 shares in the last quarter. Massmutual Trust Co. FSB ADV bought a new position in shares of Viking Therapeutics during the 1st quarter worth approximately $25,000. 9258 Wealth Management LLC grew its position in shares of Viking Therapeutics by 2.9% during the 1st quarter. 9258 Wealth Management LLC now owns 12,379 shares of the biotechnology company’s stock worth $1,015,000 after buying an additional 351 shares during the period. Crossmark Global Holdings Inc. lifted its position in shares of Viking Therapeutics by 5.5% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,457 shares of the biotechnology company’s stock valued at $395,000 after acquiring an additional 386 shares during the period. Finally, LifeSteps Financial Inc. bought a new position in Viking Therapeutics during the first quarter worth $37,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
- Five stocks we like better than Viking Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- Should You Invest in Bitcoin? Pros and Cons
- Conference Calls and Individual Investors
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- How to Invest in Insurance Companies: A Guide
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.